Charles L. Sawyers

99.4k total citations · 31 hit papers
266 papers, 53.4k citations indexed

About

Charles L. Sawyers is a scholar working on Hematology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Charles L. Sawyers has authored 266 papers receiving a total of 53.4k indexed citations (citations by other indexed papers that have themselves been cited), including 110 papers in Hematology, 98 papers in Molecular Biology and 98 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Charles L. Sawyers's work include Chronic Myeloid Leukemia Treatments (99 papers), Prostate Cancer Treatment and Research (84 papers) and Chronic Lymphocytic Leukemia Research (71 papers). Charles L. Sawyers is often cited by papers focused on Chronic Myeloid Leukemia Treatments (99 papers), Prostate Cancer Treatment and Research (84 papers) and Chronic Lymphocytic Leukemia Research (71 papers). Charles L. Sawyers collaborates with scholars based in United States, United Kingdom and Australia. Charles L. Sawyers's co-authors include Igor Vivanco, Chris Tran, Moshe Talpaz, Brian Druker, Howard I. Scher, Renaud Capdeville, Debra Resta, Hagop M. Kantarjian, John Wongvipat and J. Ford and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

Charles L. Sawyers

262 papers receiving 52.3k citations

Hit Papers

The phosphatidylinositol 3-Kinase–AKT pathway in human ca... 1997 2026 2006 2016 2002 2001 2001 2003 2009 1000 2.0k 3.0k 4.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. The phosphatidylinositol 3-Kinase–AKT pathway in human cancer
    2002 4.9k citations Igor Vivanco, Charles L. Sawyers profile →
  2. Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia
    2001 3.8k citations Brian Druker, Moshe Talpaz et al. New England Journal of Medicine profile →
  3. Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome
    2001 2.1k citations Brian Druker, Charles L. Sawyers et al. New England Journal of Medicine profile →
  4. Molecular determinants of resistance to antiandrogen therapy
    2003 1.8k citations Derek S. Welsbie, Chris Tran et al. profile →
  5. Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
    2009 1.7k citations Chris Tran, Samedy Ouk et al. Science profile →
  6. Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia
    2002 1.5k citations Charles L. Sawyers, Andreas Hochhaus et al. New England Journal of Medicine profile →
  7. Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor
    2004 1.4k citations Chris Tran, Charles L. Sawyers et al. Science profile →
  8. Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias
    2006 1.3k citations Moshe Talpaz, Hagop M. Kantarjian et al. New England Journal of Medicine profile →
  9. Chronic Myeloid Leukemia
    1999 1.3k citations Charles L. Sawyers New England Journal of Medicine profile →
  10. Granulocyte–Macrophage Progenitors as Candidate Leukemic Stem Cells in Blast-Crisis CML
    2004 1.1k citations Charles L. Sawyers et al. New England Journal of Medicine profile →
  11. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer
    2015 1.0k citations Philip A. Watson, Vivek Arora et al. profile →
  12. Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer
    2011 890 citations Brett S. Carver, John Wongvipat et al. Cancer Cell profile →
  13. Targeted cancer therapy
    2004 884 citations Charles L. Sawyers profile →
  14. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study
    2002 881 citations Charles L. Sawyers Blood profile →
  15. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study
    2010 809 citations Howard I. Scher, Tomasz M. Beer et al. profile →
  16. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR
    2001 806 citations Ingo K. Mellinghoff, Chris Tran et al. Proceedings of the National Academy of Sciences profile →
  17. Biology of Progressive, Castration-Resistant Prostate Cancer: Directed Therapies Targeting the Androgen-Receptor Signaling Axis
    2005 798 citations Howard I. Scher, Charles L. Sawyers profile →
  18. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase
    1999 780 citations Charles L. Sawyers et al. profile →
  19. The cancer biomarker problem
    2008 745 citations Charles L. Sawyers profile →
  20. Glucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor Blockade
    2013 703 citations Vivek Arora, John Wongvipat et al. Cell profile →
  21. Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance
    2017 680 citations Charles L. Sawyers et al. Science profile →
  22. A Cytoplasmic Inhibitor of the JNK Signal Transduction Pathway
    1997 597 citations Charles L. Sawyers et al. Science profile →
  23. Myc-driven murine prostate cancer shares molecular features with human prostate tumors
    2003 593 citations John Wongvipat, George Thomas et al. Cancer Cell profile →
  24. Dynamics of chronic myeloid leukaemia
    2005 592 citations Charles L. Sawyers et al. profile →
  25. Identification of Multipotent Luminal Progenitor Cells in Human Prostate Organoid Cultures
    2014 539 citations John Wongvipat, Yu Chen et al. Cell profile →
  26. The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway
    1998 539 citations Charles L. Sawyers et al. Proceedings of the National Academy of Sciences profile →
  27. Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression
    1998 526 citations Robert E. Reiter, Chris Tran et al. Proceedings of the National Academy of Sciences profile →
  28. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer
    2005 507 citations George Thomas, Chris Tran et al. profile →
  29. Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor
    2010 497 citations Philip A. Watson, John Wongvipat et al. Proceedings of the National Academy of Sciences profile →
  30. Organoid culture systems for prostate epithelial and cancer tissue
    2016 447 citations Charles L. Sawyers, Yu Chen et al. profile →
  31. Lineage plasticity in cancer: a shared pathway of therapeutic resistance
    2020 310 citations Charles L. Sawyers et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Charles L. Sawyers United States 99 24.8k 15.9k 15.8k 12.3k 11.6k 266 53.4k
Brian Druker United States 106 17.1k 0.7× 6.3k 0.4× 30.5k 1.9× 10.9k 0.9× 21.7k 1.9× 607 54.8k
Peter J. Campbell United Kingdom 77 17.9k 0.7× 2.8k 0.2× 6.4k 0.4× 5.6k 0.5× 8.2k 0.7× 251 31.8k
Francis J. Giles United States 105 15.0k 0.6× 3.4k 0.2× 20.4k 1.3× 9.3k 0.8× 15.8k 1.4× 786 41.9k
Michael Andreeff United States 112 25.9k 1.0× 2.5k 0.2× 16.0k 1.0× 13.6k 1.1× 10.3k 0.9× 1.0k 48.1k
Luis A. Díaz United States 84 13.1k 0.5× 6.5k 0.4× 1.8k 0.1× 14.6k 1.2× 7.1k 0.6× 419 40.3k
Guillermo Garcia‐Manero United States 106 17.8k 0.7× 1.9k 0.1× 30.6k 1.9× 7.5k 0.6× 14.7k 1.3× 1.5k 44.1k
James G. Herman United States 119 50.9k 2.1× 7.6k 0.5× 2.7k 0.2× 15.1k 1.2× 3.9k 0.3× 399 65.8k
Moshe Talpaz United States 98 11.0k 0.4× 2.6k 0.2× 29.2k 1.8× 8.7k 0.7× 22.8k 2.0× 778 44.8k
Carlos Cordon‐Cardo United States 129 41.4k 1.7× 11.0k 0.7× 2.3k 0.1× 22.8k 1.9× 2.5k 0.2× 564 68.1k
Daniel Birnbaum France 93 17.3k 0.7× 2.8k 0.2× 4.0k 0.3× 12.8k 1.0× 2.9k 0.3× 558 31.8k

Countries citing papers authored by Charles L. Sawyers

Since Specialization
Citations

This map shows the geographic impact of Charles L. Sawyers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Charles L. Sawyers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Charles L. Sawyers more than expected).

Fields of papers citing papers by Charles L. Sawyers

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Charles L. Sawyers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Charles L. Sawyers. The network helps show where Charles L. Sawyers may publish in the future.

Co-authorship network of co-authors of Charles L. Sawyers

This figure shows the co-authorship network connecting the top 25 collaborators of Charles L. Sawyers. A scholar is included among the top collaborators of Charles L. Sawyers based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Charles L. Sawyers. Charles L. Sawyers is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Mao, Ninghui, Young Sun Lee, Zeda Zhang, et al.. (2025). Uncoupling of Akt and mTOR signaling drives resistance to Akt inhibition in PTEN loss prostate cancers. Science Advances. 11(6). eadq3802–eadq3802. 5 indexed citations
2.
Sawyers, Charles L.. (2019). Herceptin: A First Assault on Oncogenes that Launched a Revolution. Cell. 179(1). 8–12. 37 indexed citations
3.
Spratt, Daniel E., Michael J. Evans, Brian J. Davis, et al.. (2015). Androgen Receptor Upregulation Mediates Radioresistance after Ionizing Radiation. Cancer Research. 75(22). 4688–4696. 96 indexed citations
4.
Wheeler, Douglas B., Roberto Zoncu, David E. Root, David M. Sabatini, & Charles L. Sawyers. (2015). Identification of an oncogenic RAB protein. Science. 350(6257). 211–217. 95 indexed citations
5.
Horning, Sandra J., Daniel A. Haber, Wendy Selig, et al.. (2013). Developing Standards for Breakthrough Therapy Designation in Oncology. Clinical Cancer Research. 19(16). 4297–4304. 24 indexed citations
6.
Ulmert, David, Michael J. Evans, Jason P. Holland, et al.. (2012). Imaging Androgen Receptor Signaling with a Radiotracer Targeting Free Prostate-Specific Antigen. Cancer Discovery. 2(4). 320–327. 58 indexed citations
7.
Mitsiades, Nicholas, Clifford C. Sung, Nikolaus Schultz, et al.. (2012). Distinct Patterns of Dysregulated Expression of Enzymes Involved in Androgen Synthesis and Metabolism in Metastatic Prostate Cancer Tumors. Cancer Research. 72(23). 6142–6152. 175 indexed citations
8.
Carver, Brett S., John Wongvipat, Haley Hieronymus, et al.. (2011). Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer. Cancer Cell. 19(5). 575–586. 890 indexed citations breakdown →
9.
Evans, Michael J., Peter Smith‐Jones, John Wongvipat, et al.. (2011). Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen. Proceedings of the National Academy of Sciences. 108(23). 9578–9582. 247 indexed citations
10.
Tran, Chris, Samedy Ouk, Nicola J. Clegg, et al.. (2009). Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer. Science. 324(5928). 787–790. 1689 indexed citations breakdown →
11.
Welsbie, Derek S., Jin Xu, Yu Chen, et al.. (2009). Histone Deacetylases Are Required for Androgen Receptor Function in Hormone-Sensitive and Castrate-Resistant Prostate Cancer. Cancer Research. 69(3). 958–966. 144 indexed citations
12.
Jiao, Jing, Shunyou Wang, Rong Qiao, et al.. (2007). Murine Cell Lines Derived from Pten Null Prostate Cancer Show the Critical Role of PTEN in Hormone Refractory Prostate Cancer Development. Cancer Research. 67(13). 6083–6091. 128 indexed citations
13.
14.
Sawyers, Charles L.. (2006). Will Kinase Inhibitors Have a Dark Side?. New England Journal of Medicine. 355(3). 313–315. 30 indexed citations
15.
Lu, Kan, Shaojun Zhu, Ederlyn Q. Dia, et al.. (2006). Mammalian Target of Rapamycin Inhibition Promotes Response to Epidermal Growth Factor Receptor Kinase Inhibitors in PTEN-Deficient and PTEN-Intact Glioblastoma Cells. Cancer Research. 66(16). 7864–7869. 179 indexed citations
16.
Baek, Sung Hee, Kenneth A. Ohgi, Charles A. Nelson, et al.. (2006). Ligand-specific allosteric regulation of coactivator functions of androgen receptor in prostate cancer cells. Proceedings of the National Academy of Sciences. 103(9). 3100–3105. 62 indexed citations
17.
Mellinghoff, Ingo K., Igor Vivanco, Andrew Kwon, et al.. (2004). HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell. 6(5). 517–527. 262 indexed citations
18.
Thomas, George, Steve Horvath, Bradley L. Smith, et al.. (2004). Antibody-Based Profiling of the Phosphoinositide 3-Kinase Pathway in Clinical Prostate Cancer. Clinical Cancer Research. 10(24). 8351–8356. 54 indexed citations
19.
Sawyers, Charles L.. (2002). Rational therapeutic intervention in cancer: kinases as drug targets. Current Opinion in Genetics & Development. 12(1). 111–115. 96 indexed citations
20.
Mellinghoff, Ingo K., Chris Tran, & Charles L. Sawyers. (2002). Growth inhibitory effects of the dual ErbB1/ErbB2 tyrosine kinase inhibitor PKI-166 on human prostate cancer xenografts.. PubMed. 62(18). 5254–9. 70 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Brian Druker Breakdown of academic impact, for papers by Peter J. Campbell Breakdown of academic impact, for papers by Francis J. Giles Breakdown of academic impact, for papers by Michael Andreeff Breakdown of academic impact, for papers by Luis A. Díaz Breakdown of academic impact, for papers by Guillermo Garcia‐Manero Breakdown of academic impact, for papers by James G. Herman Breakdown of academic impact, for papers by Moshe Talpaz Breakdown of academic impact, for papers by Carlos Cordon‐Cardo Breakdown of academic impact, for papers by Daniel Birnbaum
Rankless by CCL
2026